Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 5 | 2023 | 173 | 2.060 |
Why?
|
| Liver Failure | 1 | 2023 | 21 | 0.820 |
Why?
|
| Acidosis | 1 | 2023 | 36 | 0.810 |
Why?
|
| Liver Diseases | 1 | 2023 | 79 | 0.770 |
Why?
|
| Lactation | 1 | 2020 | 59 | 0.660 |
Why?
|
| Kidney Diseases | 2 | 2020 | 213 | 0.600 |
Why?
|
| Breast Feeding | 1 | 2020 | 190 | 0.580 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 29 | 0.560 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 29 | 0.560 |
Why?
|
| Renal Dialysis | 1 | 2017 | 171 | 0.510 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 202 | 0.490 |
Why?
|
| Thrombosis | 1 | 2018 | 250 | 0.470 |
Why?
|
| Phenazopyridine | 1 | 2014 | 3 | 0.450 |
Why?
|
| Nephritis, Interstitial | 1 | 2014 | 9 | 0.440 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 302 | 0.430 |
Why?
|
| Propylthiouracil | 1 | 2011 | 4 | 0.380 |
Why?
|
| Antithyroid Agents | 1 | 2011 | 8 | 0.380 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 6 | 0.380 |
Why?
|
| Graves Disease | 1 | 2011 | 19 | 0.370 |
Why?
|
| Veterans | 1 | 2018 | 573 | 0.370 |
Why?
|
| Kidney | 3 | 2023 | 690 | 0.360 |
Why?
|
| Humans | 13 | 2023 | 50417 | 0.220 |
Why?
|
| Antirheumatic Agents | 2 | 2014 | 32 | 0.210 |
Why?
|
| Bicarbonates | 1 | 2023 | 17 | 0.210 |
Why?
|
| Sodium | 1 | 2023 | 91 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2014 | 108 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 567 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2023 | 573 | 0.170 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 54 | 0.170 |
Why?
|
| Uremia | 1 | 2019 | 12 | 0.160 |
Why?
|
| Urea | 1 | 2019 | 80 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2020 | 142 | 0.150 |
Why?
|
| Nephrology | 1 | 2018 | 11 | 0.150 |
Why?
|
| Intestines | 1 | 2019 | 152 | 0.140 |
Why?
|
| Prevalence | 2 | 2018 | 967 | 0.140 |
Why?
|
| Arkansas | 1 | 2023 | 1974 | 0.140 |
Why?
|
| Hemodialysis, Home | 1 | 2017 | 8 | 0.140 |
Why?
|
| Bacteria | 1 | 2019 | 210 | 0.140 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2017 | 83 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2017 | 411 | 0.120 |
Why?
|
| Publication Bias | 1 | 2014 | 11 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 403 | 0.120 |
Why?
|
| Disease Progression | 1 | 2017 | 825 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1027 | 0.110 |
Why?
|
| Publishing | 1 | 2014 | 40 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 332 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6274 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 464 | 0.100 |
Why?
|
| Drug Industry | 1 | 2012 | 38 | 0.100 |
Why?
|
| Myeloblastin | 1 | 2011 | 3 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2012 | 45 | 0.100 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Azathioprine | 1 | 2011 | 10 | 0.100 |
Why?
|
| Heart Failure | 1 | 2017 | 531 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 39 | 0.090 |
Why?
|
| Testis | 1 | 2011 | 66 | 0.090 |
Why?
|
| Remission Induction | 1 | 2011 | 208 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 387 | 0.090 |
Why?
|
| United States | 2 | 2018 | 5005 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 227 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2011 | 233 | 0.080 |
Why?
|
| Risk Factors | 1 | 2017 | 3712 | 0.080 |
Why?
|
| Skin | 1 | 2011 | 382 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2017 | 5265 | 0.070 |
Why?
|
| Aged | 3 | 2017 | 9738 | 0.070 |
Why?
|
| Male | 4 | 2017 | 25867 | 0.070 |
Why?
|
| Biopsy | 2 | 2018 | 588 | 0.060 |
Why?
|
| Female | 3 | 2020 | 27053 | 0.060 |
Why?
|
| Adult | 3 | 2017 | 13561 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 2990 | 0.050 |
Why?
|
| Permeability | 1 | 2019 | 65 | 0.040 |
Why?
|
| Cadaver | 1 | 2018 | 95 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 214 | 0.040 |
Why?
|
| Manikins | 1 | 2018 | 35 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 134 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 52 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 119 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 137 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 136 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 120 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2017 | 83 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 658 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2017 | 360 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 449 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 271 | 0.030 |
Why?
|
| Myocardium | 1 | 2017 | 443 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 485 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1451 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2012 | 6 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 1974 | 0.020 |
Why?
|
| Middle Aged | 2 | 2017 | 12579 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 676 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 565 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 710 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3233 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 13062 | 0.010 |
Why?
|